Long-term moxifloxacin for bronchiectasis flare-ups
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests whether a long-term antibiotic called moxifloxacin is safe and effective in reducing flare-ups for people with bronchiectasis (a lung condition that causes frequent infections). If you have had at least 2 flare-ups in the past year, this trial might help you manage your symptoms better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You need a confirmed diagnosis of bronchiectasis (other than cystic fibrosis), typically based on a high-resolution CT scan of your lungs.
- You must have had at least 2 flare-ups (exacerbations) of your bronchiectasis in the past 12 months.
- You cannot have cystic fibrosis (a genetic condition that causes bronchiectasis).
- You must not have a known allergy or sensitivity to moxifloxacin or similar antibiotics (fluoroquinolones).
- You must not have severe liver or kidney problems (kidney function test eGFR below 30 mL/min).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a common antibiotic called azithromycin can help prevent flare-ups (sudden worsening) of bronchiectasis—a lung condition where airways become permanently enlarged and damaged. Patients will take azithromycin or a placebo for 12 months to see if it reduces how often they get sick.
This study helps doctors understand how severe your bronchiectasis is and predict when you might have flare-ups. You'll have routine tests over 12 months to help researchers learn more about this condition and improve future care.
This study tests if giving antibiotics (levofloxacin or gentamicin) directly into the lungs during a bronchoscopy can help patients with bronchiectasis who are in the hospital with a sudden worsening of symptoms or are on a breathing machine.
This trial studies whether long-term Staphylococcus albicans tablets can safely reduce bronchiectasis flare-ups and improve symptoms. It may help people with frequent infections/attacks due to bronchiectasis.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This study tests an oral tablet called florensocatib (also known as CHF10196) to see if it can reduce lung infections in people with bronchiectasis. It is given alongside your usual care, and may help you have fewer flare-ups.
Hear when a new Bronchiectasis, Non-Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.